Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm pediatric study of dabigatran for secondary prevention of venous thromboembolism
MOH_2017-05-10_000403Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dabigatran in venous thromboembolism (VTE), sponsored by Boehringer Ingelheim. Primary endpoint: Safety. Started Aug 2014; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on MOH_2017-05-10_000403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-10_000403.